Intravenous Cetirizine Premedication to Mitigate Infusion-Related Reactions

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Infusion-related reactions (IRRs) are a significant concern with chemotherapy, biologics, and immunotherapies.
• Intravenous (IV) diphenhydramine has been the long-standing standard for IRR prevention, despite lacking FDA approval and efficacy data.
• The FDA mandates premedication for many infusion products, increasing the need for effective antihistamines.

Purpose of the Study:

• To evaluate the efficacy and safety of IV cetirizine compared to IV diphenhydramine for preventing and managing IRRs.
• To highlight the benefits of second-generation antihistamines over first-generation options in infusion therapy.
• To present a case study of successful IRR management with IV cetirizine.

Main Methods:

• Literature review of first- and second-generation H1 antihistamines for IRR prevention.
• Comparison of safety profiles and side effects between IV diphenhydramine and IV cetirizine.
• Analysis of a clinical case demonstrating IV cetirizine's effectiveness in managing an IRR.

Main Results:

• IV cetirizine demonstrated comparable efficacy to IV diphenhydramine in reducing IRRs.
• IV cetirizine offers an improved safety profile, including less sedation and fewer anticholinergic effects.
• Potential for reduced chair time and healthcare resource utilization with IV cetirizine.

Conclusions:

• IV cetirizine is a viable and potentially superior alternative to IV diphenhydramine for preventing and treating IRRs.
• The improved safety profile of IV cetirizine makes it particularly suitable for vulnerable patient populations.
• As the landscape of infusion therapies expands, IV cetirizine should be strongly considered in premedication protocols.